Off-Label Communication Has Risks Beyond Prosecution, Sheehan Says
Pharmaceutical companies should beware of pitfalls of communicating about off-label uses even when such activities can be defended as free speech, Philadelphia Associate U.S. Attorney Jim Sheehan suggested
You may also be interested in...
States make decisions about whether to use legislation or litigation to address questionable behavior by pharmaceutical companies based on the required scope and speed of the remedial activity, Vermont Assistant Attorney General Julie Brill said
FDA's assertion of the preemption of physician labeling will likely lead to more discussions between sponsors and the agency regarding the presentation of risk information in labeling, according to Coleen Klasmeier, a former special assistant to the FDA's chief counsel
The information dissemination provisions in the FDA Modernization Act do not provide "carte blanche" for manufacturers to promote drugs off-label, the Department of Justice said in a recent letter to the Washington Legal Foundation